Olaparib Plus Abiraterone in Asian Patients With Metastatic Castration-Resistant Prostate Cancer: PROpel Subset...

Area of Science:

• Oncology
• Clinical Trials
• Prostate Cancer Research

Background:

• Metastatic castration-resistant prostate cancer (mCRPC) requires effective first-line treatments.
• The PROpel trial investigated olaparib plus abiraterone in mCRPC patients.
• Previous global data showed benefits for this combination.

Purpose of the Study:

• To report efficacy, safety, and patient-reported outcomes for the Asian subset in the PROpel trial.
• To evaluate olaparib plus abiraterone as a first-line treatment for Asian mCRPC patients.

Main Methods:

• Phase 3, randomized, double-blind trial (NCT03732820).
• 133 Asian patients with mCRPC randomly assigned to olaparib + abiraterone or placebo + abiraterone.
• Primary endpoint: investigator-assessed radiographic progression-free survival (rPFS); Key secondary endpoint: overall survival (OS).

Main Results:

• Median rPFS was 27.6 months (olaparib + abiraterone) vs. 19.3 months (placebo + abiraterone) in Asian patients (HR 0.55).
• Median OS was not reached (olaparib + abiraterone) vs. 43.7 months (placebo + abiraterone) (HR 0.59).
• Safety profile in the Asian subset was consistent with the global population.

Conclusions:

• Olaparib plus abiraterone demonstrated significant rPFS benefit in Asian mCRPC patients.
• Results were consistent with the global PROpel trial findings.
• The combination is a valuable first-line treatment option for Asian patients with mCRPC.